Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer

Cancer

Volumn 119, Issue 1, 2013, Pages 7-15

  Gonzalez Angulo, Ana M ^a   Chen, Huiqin ^a   Karuturi, Meghan S ^a   Chavez Macgregor, Mariana ^a   Tsavachidis, Spyrus ^b   Meric Bernstam, Funda ^a   Do, Kim Anh ^a   Hortobagyi, Gabriel N ^a   Thompson, Patricia A ^c   Mills, Gordon B ^a   Bondy, Melissa L ^b   Blumenschein Jr , George R ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

breast cancer; catalytic subunit of phosphoinositide 3 kinase (PIK3CA); gene copy number; MET; prognosis

Indexed keywords

ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COPY NUMBER VARIATION; DISEASE ASSOCIATION; DNA DETERMINATION; DNA EXTRACTION; ENZYME ACTIVE SITE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ALGORITHM; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MET GENE; MOLECULAR INVERSION PROBES ASSAY; MOLECULAR PROBE; PIK3CA GENE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CATALYTIC DOMAIN; DISEASE-FREE SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE DOSAGE; GENE FREQUENCY; HUMANS; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872823067     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27608     Document Type: Article

References (32)

1. Stoker M, Gherardi E, Perryman M, Gray J,. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987; 327: 239-242.
2. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989; 342: 440-443.
3. Miyazawa K, Tsubouchi H, Naka D, et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun. 1989; 163: 967-973.
4. Zarnegar R, Michalopoulos G,. Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res. 1989; 49: 3314-3320.
5. Gherardi E, Stoker M,. Hepatocytes and scatter factor. Nature. 1990; 346: 228.
6. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991; 251: 802-804.
7. Weidner KM, Arakaki N, Hartmann G, et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA. 1991; 88: 7001-7005.
8. Ma PC, Maulik G, Christensen J, Salgia R,. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003; 22: 309-325.
9. Boix L, Rosa JL, Ventura F, et al. c-Met mRNA overexpression in human hepatocellular carcinoma. Hepatology. 1994; 19: 88-91.
10. Ichimura E, Maeshima A, Nakajima T, Nakamura T,. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res. 1996; 87: 1063-1069.
11. Edakuni G, Sasatomi E, Satoh T, Tokunaga O, Miyazaki K,. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int. 2001; 51: 172-178.
12. Ayhan A, Ertunc D, Tok EC, Ayhan A,. Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance. Int J Gynecol Cancer. 2005; 15: 618-623.
13. Danilkovitch-Miagkova A, Zbar B,. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest. 2002; 109: 863 -;867.
14. Yamashita J, Ogawa M, Yamashita S, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. 1994; 54: 1630-1633.
15. Parr C, Watkins G, Mansel RE, Jiang WG,. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res. 2004; 10 (1 pt 1): 202-211.
16. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB,. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005; 4: 988-1004.
17. Meric-Bernstam F, Gonzalez-Angulo AM,. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009; 27: 2278-2287.
18. Agarwal R, Carey M, Hennessy B, Mills GB,. PI3K pathway-directed therapeutic strategies in cancer. Curr Opin Investig Drugs. 2010; 11: 615-628.
19. Gewinner C, Wang ZC, Richardson A, et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell. 2009; 16: 115-125.
20. Miller TW, Perez-Torres M, Narasanna A, et al. Loss of phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res. 2009; 69: 4192-4201.
21. Perez-Tenorio G, Stal O,; Southeast Sweden Breast Cancer Group. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer. 2002; 86: 540-545.
22. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6: 117-127.
23. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007; 12: 395-402.
24. McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM,. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer. 2010;(suppl 3): S59-S65.
25. Lengyel E, Prechtel D, Resau JH, et al. c-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2005; 113: 678-682.
26. Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL,. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer. 1998; 82: 1513-1520.
27. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM,. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009; 15: 2207-2214.
28. Saal LH, Johansson P, Holm K, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A. 2007; 104: 7564-7569.
29. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008; 68: 6084-6091.
30. Wu G, Xing M, Mambo E, et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 2005; 7: R609-R616.
31. Kadota M, Sato M, Duncan B, et al. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res. 2009; 69: 7357-7365.
32. Lopez-Knowles E, O'Toole SA, McNeil CM, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer. 2010; 126: 1121-1131.